Oncology EPCS Integration: Secure and Compliant Controlled Substance Prescribing

Achieving compliant and efficient oncology EPCS integration is paramount for cancer care providers managing complex treatment regimens and supportive care needs.

Oncology practices navigate an exceptionally high volume of prior authorizations for high-cost biologics, infusion therapies, and advanced imaging. Simultaneously, the secure and compliant electronic prescribing of controlled substances (EPCS) for pain management and supportive care adds another layer of administrative and technical complexity.

The Dual Imperative: PA and EPCS in Oncology

Oncology experiences among the highest prior authorization volumes for categories like J-code chemotherapy and biologic infusions, advanced imaging for staging, radiation oncology procedures, and specialty oral oncolytics. Concurrently, patients require controlled substances for pain and symptom management, necessitating robust DEA EPCS compliance within the clinical workflow.

EPCS Requirements in the Cancer Care Context

DEA EPCS mandates secure electronic prescribing for controlled substances, replacing paper prescriptions to enhance security and reduce fraud. In oncology, this applies to critical supportive care medications, including certain antiemetics, anxiolytics, and pain medications essential for patient quality of life and adherence to complex treatment regimens.

Challenges of EPCS Integration in Oncology Workflows

Integrating DEA EPCS securely into the EMR while managing frequent regimen changes and dozens of PA events per patient presents unique challenges. The process requires robust identity verification, often leveraging solutions from trusted providers like Imprivata or Identity Automation, ensuring that prescribing workflows remain efficient without compromising compliance or patient safety.

Klivira's Unified Platform for Oncology Workflows

Klivira's platform is designed to integrate seamlessly with existing EMRs, addressing both the high prior authorization burden and EPCS requirements specific to oncology. Our NCCN-compendium-aware policy logic streamlines prior authorizations for chemotherapy regimens and biologics, while also supporting secure EPCS workflows for controlled substances, whether they fall under medical or pharmacy benefit.

Optimizing Compliance and Patient Access

By integrating EPCS directly into the oncology EMR, practices can enhance compliance with DEA standards and improve patient safety by reducing errors associated with manual prescribing. This streamlined approach ensures that patients receive timely access to necessary pain management and supportive care medications, minimizing delays in their critical treatment journey.

Frequently asked questions

What is DEA EPCS and why is it critical for oncology?

DEA EPCS (Electronic Prescribing of Controlled Substances) is a federal mandate requiring controlled substances to be prescribed electronically. In oncology, it ensures secure and compliant prescribing of medications for pain management, antiemetics, and other supportive care, reducing diversion risk and improving patient safety.

How does EPCS integration impact oncology prior authorization workflows?

While distinct processes, both EPCS and prior authorization occur within the EMR. Effective integration means that the secure EPCS workflow for controlled substances can coexist efficiently with the complex PA processes for high-cost biologics or radiation therapy, preventing bottlenecks and ensuring comprehensive patient care.

Which identity providers are commonly used for EPCS in oncology?

For DEA EPCS compliance, robust identity verification is essential. Common identity providers that integrate with EMRs to facilitate secure EPCS include Imprivata and Identity Automation, ensuring that only authorized prescribers can electronically sign controlled substance prescriptions.

How does Klivira support both oncology PA and EPCS integration?

Klivira's platform integrates with your EMR to manage the full spectrum of oncology workflows. This includes NCCN-compendium-aware automation for prior authorizations across medical and pharmacy benefits, alongside secure integration for DEA EPCS, streamlining both administrative burdens within a unified system.

What are the key benefits of robust EPCS integration for oncology practices?

Robust EPCS integration in oncology enhances compliance with federal regulations, improves patient safety by reducing prescription errors and fraud, and streamlines clinical workflows. It allows oncologists to securely prescribe necessary controlled substances without disrupting complex treatment plans or PA processes.